NEWS!!!
Altachem Pharma completes technology transfer for HCG molecule
Altachem Pharma Ltd AAF
Shares issued 14,735,899 1999-06-08 close $0.5
Tuesday Jun 15 1999
Mr. Warren Jackson reports
Altachem Pharma Ltd. has completed the technology transfer (entire rights to the patent rights to make, have made, use, lease, sell, import and export technology products and to practice the technology process) in the territory (shall mean the world) with the University of Montreal and Dr. Tony Antakly, for the HCG molecule and the option for two retenoids.
Dr. Tony Antakly, professor of biochemistry at the University of Montreal and director of the molecular biopathology laboratory discovered a novel protein with potent anti-HIV and Kaposi's sarcoma activity, which he extracted from pregnancy urine. Laboratory studies indicate that molecules associated with the pregnancy hormone HCG may be effective against AIDS and its associated cancer Kaposi's sarcoma. Thus, this discovery provides a solid basis for development of a novel Kaposi sarcoma and AIDS therapy. The molecule is dubbed as HIP (HCG-like and HIV inhibitory protein). Laboratory experiments have shown that HCG preparations display significant inhibitory action on KS cell growth as well as demonstrating its anti-HIV activity. Furthermore, HIP treatment of human lymphocytes infected with the HIV virus resulted in a significant inhibition of HIV expression. A world patent has been submitted for the HIP molecule. At the moment, the HIP molecule is in preclinical status.
The current HAART (highly active antiretroviral therapy) commonly used for HIV treatment, though effective, display nonetheless severe side effects. Furthermore, resistance to the drugs is now emerging after over two years of widespread use. The prolonged administration of these HAART therapies in some cases necessitate discontinuation. Alternative therapies are urgently required. Natural substances, including hormones, antihormones and its analogues, are increasingly being used as milder therapeutic agents which target specific receptor-expressing cells.
Anticort status
Since obtaining the health protection branch "no objection" letter to proceed with clinical trials, the proposed clinical study has been submitted to the institutional ethics board for its approval to start the clinical trials.
If the safety and efficiency of these three natural molecules (HIP and the two retenoids) and Anticort can be positively demonstrated in the human clinical trials, then Altachem Pharma will proceed to develop and formulate its own AIDS drugs. These are expected to provide a milder therapeutic treatment, with fewer side effects than the current HAART therapies.
Altachem Pharma Ltd. is participating, via a trade booth and presentation, in a technology investment forum in Edmonton, Alta., on June 22, 1999, at the Delta Edmonton South Hotel and Conference Centre and in Calgary, Alta., on June 24, 1999, at the Calgary Convention Centre. These single-day events offer you the opportunity to meet directly with the management team of Altachem Pharma Ltd. to learn first-hand from newsletter editor panels and financial analysts about investment opportunities. Please come and visit the company's booth. For more information on attending the Cambridge House international forum, call 1-877-363-3356.
WARNING: The company relies on litigation protection for "forward-looking" statements.
(c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com |
